Newsletter Tool

Featured Story

AstraZeneca in talks to produce COVID-19 vaccine for feds at Catalent site in Maryland: report

By Fraiser Kansteiner

With production nixed at a Baltimore plant—and its shot’s role in the U.S. vaccination scheme uncertain—AstraZeneca may turn to one of its established pandemic manufacturing partners to crank out doses for the feds.

Valneva's not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

By Noah Higgins-Dunn

Valneva’s COVID-19 vaccine could bring in roughly $1.1 billion in 2022 revenues through supply deals and more than $500 million in 2023, Jefferies analysts predicted. The vaccine, dubbed VLA2001, is currently in late-stage trials with a readout expected in the third quarter.

Solera Health partners with Headspace to expand mental health tools for payers, employers

By Heather Landi

Solera Health is teaming up with Headspace to offer the startup's meditation, mindfulness and mental training app directly to payer and employer member populations.

COVID-19 tracker: Roche, Regeneron strike EU deal for antibody cocktail

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

The Biden administration said it would give the vaccine sharing facility COVAX 75%, or roughly 19 million doses, of the first 25 million doses it will donate to other countries. The European Union secured 55,000 doses of the Roche-Regeneron antibody cocktail for non-hospitalized patients. And more headlines.

New House and Senate bill aims to tackle primary care doctor shortage

By Robert King

Congress is pursuing legislation that would boost funding for graduate medical education by $500 million in an effort to head off a shortage of primary care physicians.

COVID-19 Tracker